The ruthenium-based anticancer drug KP1339/IT-139 has been developed by the Bernhard Keppler Group of the Institute of Inorganic Chemistry in cooperation with the Medical University Vienna and the Research Cluster Translational Cancer Therapy Research. It is currently undergoing clincal studies in USA in cooperation with Intezyne, Inc. (Tampa, FL).
- Press release of the University of Vienna (in German): 19 April 2018: Neuer Wirkmechanismus von Tumortherapeutikum entdeckt
- Press release published by Intezyne:13 April 2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting
- Press release, 20 Juli 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer
- Wernitznig D, Del Favero G, Kiakos K, et al, KP-1339 (IT-139) induces the hallmarks of immunogenic cell death in a colon cancer 3D model in vitro
- Burris HA, Bakewell S, Bendell JC, et al, Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort, ESMO Open 2016
- Website Intezyne: IT-139
